Skip to Content

Markets
Technicals
Companies
Earnings
Close-Up
Themes

News

Market and company headlines

ZURAAll

Loading

A personal project for following the US markets. Free, ad-free and open source.

Weekly Recap

Every Sunday morning: the week's earnings behind you and the calendar ahead, in one email.

Get It by Email

Market

Markets
Companies
Stock Screener
Macro
Earnings
Technical Analysis
Calendar
Compare
Thematic Lists
Famous Investors

Reading

Guide
Close-Up
Community
News
Brief Archive
Glossary
Tax Calculator
RSS

Account

Watchlist
My Posts
Bell Report
Portfolio
Settings
Privacy

© 2026 Opening BellPrivacy About What's New ContactNot Investment AdviceAhmet Akyapı

Markets Earnings Close-Up Menu

Nasdaq 100 · QQQ721.22+ 1.27%S&P 500 · SPY769.93+ 0.60%Dow Jones · DIA523.42+ 0.09%Russell 2000 · IWM280.07+ 1.11%

These stocks have an unusual volume in today's session
Volume analysis on 2026-10-14: stocks with an unusual volume in today's session.
ChartMill13:0013 Days Ago

04:00Oct 71 Story

This biotech stock is a top pick at Guggenheim
Investing.com-- Guggenheim named Zura Bio a top pick in the biotechnology sector, reiterating its Buy rating and $20 price target ahead of the company’s Phase II TibuSHIELD readout in hidradenitis suppurativa, expected in the fourth quarter of 2026.
Yahoo04:00ZURA+20.1%

01:00Sep 111 Story

Zura Bio (ZURA) Hits Enrollment Milestones As Losses Widen Sharply
On August 11, Zura Bio (NASDAQ:ZURA) reported second-quarter results that landed on an unusual mix of good and bad news. The clinical-stage biotech finished enrolling two separate Phase 2 studies of its lead drug, tibulizumab, both ahead of their original targets, while a widening net loss showed just how much it costs to run them. […]
Yahoo01:35ZURA+20.1%

04:00-09:00Aug 122 Stories

Wedbush Maintains Outperform on Zura Bio, Raises Price Target to $22
Wedbush analyst Martin Fan maintains Zura Bio (NASDAQ:ZURA) with a Outperform and raises the price target from $15 to $22.
Benzinga08:00ZURA+20.1%
Guggenheim Maintains Buy on Zura Bio, Raises Price Target to $20
Guggenheim analyst Yatin Suneja maintains Zura Bio (NASDAQ:ZURA) with a Buy and raises the price target from $15 to $20.
Benzinga04:28ZURA+20.1%

03:00Aug 111 Story

Zura Bio Q2 EPS $(0.21) Misses $(0.20) Estimate
Zura Bio (NASDAQ:ZURA) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 5 percent. This is a 23.53 percent decrease over losses of $(0.17) per share from the same
Benzinga03:43ZURA+20.1%